FDA panel recommends approval of Epizyme drug for rare cancer – MedCity News

The agency’s Oncologic Drugs Advisory Committee voted unanimously to recommend approval of tazemetostat for epithelioid sarcoma. The company has said it would likely use drugs like Bristol-Myers Squibb’s Revlimid as a benchmark for pricing.

Read the full article here

Related Articles